Previous 10 | Next 10 |
Precigen Announces Merck KGaA, Darmstadt, Germany Increases Ownership Position Through Exercise of Convertible Note PR Newswire GERMANTOWN, Md., Oct. 9, 2020 GERMANTOWN, Md. , Oct. 9, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceut...
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Precigen, Inc. (PGEN), f/k/a Intrexon Corp. (XON) Investors with Losses to Contact Its Attorneys PR Newswire SAN FRANCISCO, Oct. 6, 2020 SAN FRANCISCO , Oct. 6, 2020 /PRNewswire/ -- Hagens Berman urges ...
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Precigen, Inc. (PGEN), f/k/a Intrexon Corp. (XON) Investors with Losses to Contact Its Attorneys, SEC Finds Company Violated Securities Laws PR Newswire SAN FRANCISCO, Oct. 2, 2020 SAN FRANCISCO , Oct. 2, 2020...
Precigen, Inc., formerly Intrexon, is a synthetic biology company transitioning to a self-reliant discovery and clinical-stage corporation advancing next-generation gene/cellular therapies. Precigen has undergone an aggressive managerial/strategy change in 1H 2020, replacing CEO Randa...
The following slide deck was published by Precigen, Inc. in conjunction with this Read more ...
GERMANTOWN, Md. , Sept. 8, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari , PhD, President and CEO of Pr...
Precigen (NASDAQ: PGEN ) +1.8% in premarket, has dosed first patient with its's PRGN-2009 in Phase 1/2 trial . The product candidate is an off-the-shelf immunotherapy that utilizes AdenoVerse platform designed to activate the immune system to recognize and tar...
GERMANTOWN, Md. , Aug. 17, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today announced that the first patient has been dosed with Precigen...
Insider buying increased last week, with insiders purchasing $283.47 million of stock compared to $172.17 million in the week prior. Selling decreased, with insiders selling $3.58 billion of stock last week compared to $5.71 billion in the week prior. Sell/Buy Ratio: The insider Sell/Buy r...
Precigen (NASDAQ: PGEN ) +5% on disclosing that its Chairman Randal Kirk bought an aggregate of 1.2M shares for $5.35M. More news on: Precigen, Inc., Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
2024-06-03 14:30:04 ET Stifel Nicolaus analyst issues MARKET OUTPERFORM recommendation for PGEN on June 3, 2024 01:00PM ET. The previous analyst recommendation was Market Outperform. PGEN was trading at $1.53 at issue of the analyst recommendation. The overall analyst co...
2024-06-03 14:30:03 ET JMP Securities analyst issues UNDERPERFORM recommendation for PGEN on June 3, 2024 01:00PM ET. The previous analyst recommendation was Underperform. PGEN was trading at $1.53 at issue of the analyst recommendation. The overall analyst consensus : B...
Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response PR Newswire – Phase 1/2 pivotal study met the primary safety and efficacy endpoints ...